Drug Type Small molecule drug |
Synonyms TG-2349 |
Target |
Action inhibitors |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC47H56N6O10S |
InChIKeyGZRNOYTVBWWFLJ-NTPALUMKSA-N |
CAS Registry1435923-88-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 3 | China | 13 Jun 2019 | |
Fibrosis | Phase 3 | China | 13 Jun 2019 | |
Hepatitis C, Chronic | Phase 3 | China | 13 Jun 2019 | |
Chronic hepatitis C genotype 1b | Phase 2 | Taiwan Province | 01 May 2015 | |
Hepatitis C | Phase 2 | United States | 11 Sep 2013 |
Phase 2 | 25 | (Group I) | xdmjpcayhn = bfdewcmlhe tagselrdhu (jgixcklvcu, pkchgxxgwd - aivmvdxlel) View more | - | 12 Oct 2018 | ||
(Group II) | xdmjpcayhn = ygkcjwwfqz tagselrdhu (jgixcklvcu, zmcexdhfuw - lfjvxnhezr) View more |